A 35-year-old woman presents with heavy menstrual bleeding. She reports using 12 pads per day during her periods, passing large clots, and flooding through to her clothes. Her periods last 8 days and occur regularly every 28 days. She has two children and may wish for more in the future. Examination is unremarkable. Which investigation is most important to perform first?
Q132
According to current UK guidelines, what is the discriminatory beta-hCG level above which a transvaginal ultrasound scan should reliably identify an intrauterine gestational sac in a viable intrauterine pregnancy?
Q133
A 42-year-old woman presents with a 4-month history of heavy, prolonged menstrual periods occurring every 18-35 days. She also reports hot flushes and night sweats. Blood tests show: FSH 58 IU/L, LH 42 IU/L, oestradiol 45 pmol/L, haemoglobin 102 g/L. Transvaginal ultrasound shows endometrial thickness of 6mm and normal ovaries. What is the underlying cause of her abnormal bleeding?
Q134
A 26-year-old woman who is 6 weeks pregnant following IVF treatment presents with right iliac fossa pain and spotting. Transvaginal ultrasound shows an intrauterine gestational sac with a yolk sac and fetal pole with visible cardiac activity (crown-rump length 5mm). Additionally, a 30mm right adnexal mass with a hyperechoic ring is identified. Serum beta-hCG is 15,000 IU/L. She is haemodynamically stable. What is the most appropriate management?
Q135
A 38-year-old woman with known uterine fibroids presents with heavy menstrual bleeding not controlled by medical management. She experiences flooding every 26 days lasting 10 days and has failed treatment with tranexamic acid and the levonorgestrel intrauterine system. Her haemoglobin is 82 g/L. Pelvic MRI shows a 9 cm intramural fibroid and multiple smaller fibroids. She wishes to preserve her uterus. Which treatment option would be most appropriate?
Q136
A 19-year-old woman presents to the emergency department with sudden onset right-sided abdominal pain and minimal vaginal bleeding. She had a positive pregnancy test at home 3 days ago. Her last menstrual period was 5 weeks ago. Observations: BP 115/75 mmHg, pulse 88 bpm, temperature 36.8°C. Transvaginal ultrasound shows an empty uterus and no adnexal masses. Free fluid is noted in the pouch of Douglas. Serum beta-hCG is 1,200 IU/L. What is the most appropriate initial management?
Q137
A 52-year-old perimenopausal woman presents with intermenstrual bleeding and post-coital bleeding over the past 3 months. She had normal cervical screening 18 months ago. On speculum examination, the cervix appears normal. Transvaginal ultrasound shows endometrial thickness of 18 mm with heterogeneous appearance. What is the most appropriate next investigation?
Q138
A 32-year-old nulliparous woman presents with 6 weeks amenorrhoea and mild lower abdominal pain. Transvaginal ultrasound shows an empty uterus with 15 mm endometrial thickness and a 25 mm adnexal mass with a hyperechoic ring. Serum beta-hCG is 2,100 IU/L. She is haemodynamically stable and wishes to preserve her fertility. A repeat beta-hCG 48 hours later is 3,800 IU/L. What is the most appropriate management?
Q139
A 45-year-old woman attends the gynaecology clinic with a 6-month history of increasingly heavy menstrual bleeding. Her periods occur regularly every 28 days but last 9 days with flooding and clots. She has completed her family. Blood tests show haemoglobin 95 g/L, MCV 72 fL. Transvaginal ultrasound reveals a normal-sized uterus with 12 mm endometrial thickness and no structural abnormalities. What is the most appropriate first-line pharmacological treatment?
Q140
A 28-year-old woman presents to the emergency department with sudden onset severe left iliac fossa pain and vaginal bleeding. Her last menstrual period was 7 weeks ago. She has a history of pelvic inflammatory disease. On examination, she is pale, blood pressure 95/60 mmHg, pulse 110 bpm. Abdominal examination reveals tenderness and guarding in the left iliac fossa. A urine pregnancy test is positive. What is the most appropriate immediate management?
Gynaecology UK Medical PG Practice Questions and MCQs
Question 131: A 35-year-old woman presents with heavy menstrual bleeding. She reports using 12 pads per day during her periods, passing large clots, and flooding through to her clothes. Her periods last 8 days and occur regularly every 28 days. She has two children and may wish for more in the future. Examination is unremarkable. Which investigation is most important to perform first?
A. Transvaginal ultrasound scan
B. Thyroid function tests
C. Full blood count (Correct Answer)
D. Coagulation screen
E. Serum ferritin
Explanation: ***Full blood count***- According to clinical guidelines, an **FBC** should be performed for all women with **heavy menstrual bleeding (HMB)** to identify **iron-deficiency anaemia**.- This patient's symptoms of **flooding**, passing **large clots**, and using 12 pads per day objectively indicate significant blood loss that prioritizes the assessment of **haemoglobin levels**.*Transvaginal ultrasound scan*- A **TVUS** is indicated to identify structural pathologies like **fibroids** or **adenomyosis**, but it is generally performed after or alongside initial blood tests.- While important for diagnosis, it does not assess the immediate physiological impact of the bleeding, such as **anaemia**.*Thyroid function tests*- **Hypothyroidism** can be a cause of HMB, but routine testing is not recommended unless other clinical signs of **thyroid dysfunction** are present.- This patient's examination is **unremarkable**, making thyroid pathology a less likely primary concern than the immediate risk of anaemia.*Coagulation screen*- Testing for **coagulation disorders** (like von Willebrand disease) is indicated if a woman has had HMB since **menarche** or a personal/family history of bleeding.- Since this patient has already had two children without reported complications, a primary **clotting disorder** is less likely to be the initial diagnostic priority.*Serum ferritin*- While **ferritin** assesses **iron stores**, the **FBC** is the more critical first step as it determines the actual **haemoglobin concentration** and presence of anaemia.- Ferritin is often tested concurrently, but it does not replace the necessity of checking for a **low haematocrit** or **thrombocytopenia** on FBC.
Question 132: According to current UK guidelines, what is the discriminatory beta-hCG level above which a transvaginal ultrasound scan should reliably identify an intrauterine gestational sac in a viable intrauterine pregnancy?
A. 500 IU/L
B. 1,500 IU/L (Correct Answer)
C. 1,000 IU/L
D. 2,500 IU/L
E. 3,000 IU/L
Explanation: ***1,500 IU/L***
- In UK practice, **1,500 IU/L** is the established **discriminatory level** where a gestational sac should be visible via **transvaginal ultrasound (TVUS)** in a viable pregnancy.
- If levels exceed this threshold without a visible intrauterine sac, the risk of an **ectopic pregnancy** or **pregnancy of unknown location (PUL)** is significantly increased.
*500 IU/L*
- This level is too low to reliably expect visualization of a **gestational sac** even with high-resolution **transvaginal imaging**.
- Clinical management at this level usually involves serial **beta-hCG monitoring** to assess the trend before definitive imaging diagnoses can be made.
*1,000 IU/L*
- While some older literature or specific institutions may use **1,000 IU/L**, it is not the standard threshold cited by current **UK guidelines** (such as NICE).
- Using a lower threshold increases the risk of **false-positive** diagnoses of ectopic pregnancy in early, viable **intrauterine pregnancies**.
*2,500 IU/L*
- A level of **2,500 IU/L** is much higher than the standard discriminatory zone and would clearly necessitate a visible sac on **ultrasound**.
- This threshold is sometimes used for **transabdominal scans**, which are less sensitive than the **transvaginal** approach used in early pregnancy assessment.
*3,000 IU/L*
- At **3,000 IU/L**, a viable pregnancy would almost certainly be visible; however, this value is unnecessary as a **diagnostic threshold** for TVUS.
- Waiting for the hCG to reach this level before investigating for **ectopic pregnancy** would cause dangerous delays in clinical management.
Question 133: A 42-year-old woman presents with a 4-month history of heavy, prolonged menstrual periods occurring every 18-35 days. She also reports hot flushes and night sweats. Blood tests show: FSH 58 IU/L, LH 42 IU/L, oestradiol 45 pmol/L, haemoglobin 102 g/L. Transvaginal ultrasound shows endometrial thickness of 6mm and normal ovaries. What is the underlying cause of her abnormal bleeding?
A. Anovulatory cycles secondary to premature ovarian insufficiency (Correct Answer)
B. Endometrial hyperplasia
C. Polycystic ovary syndrome
D. Hypothyroidism
E. Adenomyosis
Explanation: ***Anovulatory cycles secondary to premature ovarian insufficiency***- The patient's significantly **elevated FSH (58 IU/L)** and **LH (42 IU/L)**, coupled with **low oestradiol (45 pmol/L)** at age 42, are classic indicators of **premature ovarian insufficiency (POI)**.- These hormonal changes result in **anovulation**, leading to unstable endometrial lining and subsequently **heavy, prolonged, and irregular menstrual bleeding**, along with **vasomotor symptoms** like hot flushes and night sweats due to hypoestrogenism.*Endometrial hyperplasia*- This condition typically arises from **unopposed oestrogen stimulation**, leading to a thickened endometrium, usually much greater than the **6mm** measured in this case.- The patient's **low oestradiol** level contradicts the hormonal environment required for endometrial hyperplasia to develop.*Polycystic ovary syndrome*- While PCOS can cause anovulatory cycles and irregular bleeding, it typically features **normal or low FSH** levels and often an **elevated LH:FSH ratio**, which is opposite to the high FSH and LH observed here.- PCOS diagnosis also requires evidence of **hyperandrogenism** (clinical or biochemical) or polycystic ovarian morphology, neither of which is presented in this case.*Hypothyroidism*- Hypothyroidism can cause menstrual irregularities such as **menorrhagia**, but it does not account for the **markedly elevated FSH and LH** or the low oestradiol levels seen in this patient.- The patient's prominent **vasomotor symptoms** (hot flushes, night sweats) are more characteristic of hypoestrogenism rather than hypothyroidism.*Adenomyosis*- Adenomyosis is a structural uterine disorder characterized by **heavy menstrual bleeding (menorrhagia)** and often painful periods (dysmenorrhea), typically presenting with a **globally enlarged uterus**.- It is a uterine pathology and does not cause the **hypergonadotropic hypogonadism** (high FSH/LH, low oestrogen) and **vasomotor symptoms** that are central to this patient's presentation.
Question 134: A 26-year-old woman who is 6 weeks pregnant following IVF treatment presents with right iliac fossa pain and spotting. Transvaginal ultrasound shows an intrauterine gestational sac with a yolk sac and fetal pole with visible cardiac activity (crown-rump length 5mm). Additionally, a 30mm right adnexal mass with a hyperechoic ring is identified. Serum beta-hCG is 15,000 IU/L. She is haemodynamically stable. What is the most appropriate management?
A. Expectant management with close monitoring
B. Methotrexate therapy
C. Laparoscopic salpingectomy (Correct Answer)
D. Potassium chloride injection into ectopic pregnancy
E. Bilateral salpingectomy
Explanation: ***Laparoscopic salpingectomy***
- This patient presents with a **heterotopic pregnancy**, a simultaneous intrauterine and ectopic pregnancy, a known increased risk following **IVF** treatment.
- **Laparoscopic salpingectomy** is the definitive treatment for the ectopic component, removing the 30mm tubal mass and alleviating symptoms while preserving the viable **intrauterine gestation**.
*Expectant management with close monitoring*
- The 30mm adnexal mass and symptoms of pain and spotting indicate a high risk of **tubal rupture**, making expectant management unsafe and inappropriate.
- **Expectant management** is usually reserved for very small, asymptomatic ectopics with falling beta-hCG, which is not the case with a viable intrauterine pregnancy and symptoms.
*Methotrexate therapy*
- **Methotrexate** is strictly **contraindicated** in this scenario as it is a folate antagonist and would harm or terminate the viable **intrauterine pregnancy**.
- Its use is limited to isolated ectopic pregnancies without a concomitant viable intrauterine gestation.
*Potassium chloride injection into ectopic pregnancy*
- While used for selective reduction, **KCl injection** is less definitive for a tubal ectopic compared to surgical removal and carries risks of incomplete resolution.
- It is typically considered for specific types of ectopic pregnancies (e.g., interstitial, cervical) where surgical access might be more challenging.
*Bilateral salpingectomy*
- There is no medical indication to remove the healthy contralateral fallopian tube, as the problem is a **unilateral ectopic pregnancy**.
- **Bilateral salpingectomy** would unnecessarily increase surgical morbidity and compromise future fertility without offering additional benefit for the current situation.
Question 135: A 38-year-old woman with known uterine fibroids presents with heavy menstrual bleeding not controlled by medical management. She experiences flooding every 26 days lasting 10 days and has failed treatment with tranexamic acid and the levonorgestrel intrauterine system. Her haemoglobin is 82 g/L. Pelvic MRI shows a 9 cm intramural fibroid and multiple smaller fibroids. She wishes to preserve her uterus. Which treatment option would be most appropriate?
A. Uterine artery embolization (Correct Answer)
B. Total abdominal hysterectomy
C. Myomectomy
D. Endometrial ablation
E. High-intensity focused ultrasound
Explanation: ***Uterine artery embolization***- **Uterine artery embolization (UAE)** is a highly effective, minimally invasive procedure for treating symptomatic **multiple fibroids** while allowing for **uterine preservation**.- It is particularly suitable for this patient who has failed medical management and has **symptomatic bulk** (9 cm fibroid) that needs reduction without major surgery.*Total abdominal hysterectomy*- This procedure involves the **permanent removal** of the uterus, which directly contradicts the patient's explicit wish to **preserve her uterus**.- While it provides a definitive cure for **heavy menstrual bleeding**, it carries the highest surgical morbidity and longest recovery time among the options.*Myomectomy*- Although it preserves the uterus, the presence of **multiple fibroids** and a large **9 cm intramural fibroid** makes this surgically complex and increases the risk of significant intraoperative **haemorrhage**.- There is a high risk of **fibroid recurrence** from the smaller existing fibroids, potentially necessitating further interventions in the future.*Endometrial ablation*- This procedure is typically **contraindicated** when the uterine cavity is significantly distorted by large **intramural or submucosal fibroids** greater than 3 cm.- It only treats the **endometrial lining** and would not address the symptoms caused by the large **fibroid bulk** or the 9 cm intramural mass.*High-intensity focused ultrasound*- **HIFU** is a newer, less invasive option, but it has **limited availability** and a smaller evidence base compared to established treatments like UAE.- It may be less effective for treating **multiple large fibroids** simultaneously compared to the global effect achieved by embolizing the uterine arteries.
Question 136: A 19-year-old woman presents to the emergency department with sudden onset right-sided abdominal pain and minimal vaginal bleeding. She had a positive pregnancy test at home 3 days ago. Her last menstrual period was 5 weeks ago. Observations: BP 115/75 mmHg, pulse 88 bpm, temperature 36.8°C. Transvaginal ultrasound shows an empty uterus and no adnexal masses. Free fluid is noted in the pouch of Douglas. Serum beta-hCG is 1,200 IU/L. What is the most appropriate initial management?
A. Repeat serum beta-hCG in 48 hours (Correct Answer)
B. Immediate laparoscopy
C. Single dose methotrexate
D. Expectant management with weekly beta-hCG
E. Uterine curettage
Explanation: ***Repeat serum beta-hCG in 48 hours***
- This patient presents with a **pregnancy of unknown location (PUL)**, as her serum beta-hCG (1,200 IU/L) is below the **discriminatory zone** (typically 1,500–2,000 IU/L) where an intrauterine pregnancy should be visible on transvaginal ultrasound.
- In a **haemodynamically stable** patient, serial beta-hCG measurements every 48 hours are crucial to establish the trend (rising appropriately, rising suboptimally, or falling) to differentiate between a viable **intrauterine pregnancy**, an **ectopic pregnancy**, or a **miscarriage**.
*Immediate laparoscopy*
- Surgical intervention is indicated for patients who are **haemodynamically unstable** or have definitive ultrasound evidence of a **ruptured ectopic pregnancy** (e.g., large amount of free fluid, definite adnexal mass with features of rupture).
- This patient is clinically stable, and the ultrasound shows an empty uterus with no adnexal masses, making immediate surgery premature and potentially unnecessary.
*Single dose methotrexate*
- Methotrexate is a medical management option for a **confirmed ectopic pregnancy** that meets specific criteria (e.g., hCG <5,000 IU/L, no fetal cardiac activity, patient stability).
- Administering it before further characterization of the PUL carries the risk of inadvertently terminating a potentially viable **early intrauterine pregnancy** if the beta-hCG were to rise normally.
*Expectant management with weekly beta-hCG*
- Expectant management with weekly monitoring is generally reserved for patients with very low or already **falling beta-hCG levels**, often suggesting a resolving pregnancy of unknown location or a complete miscarriage.
- At this initial stage of PUL with an hCG of 1,200 IU/L, a **48-hour interval** is required to establish the biochemical trend swiftly and guide further management, rather than waiting a full week.
*Uterine curettage*
- Uterine curettage is typically performed to obtain **chorionic villi** for histological confirmation, primarily to distinguish between a non-viable intrauterine pregnancy and an ectopic pregnancy if serial hCG levels are not conclusive or are persistently high without an identifiable IUP.
- It is an invasive procedure and not an initial management step for a stable patient with PUL, especially when an early viable IUP cannot be ruled out.
Question 137: A 52-year-old perimenopausal woman presents with intermenstrual bleeding and post-coital bleeding over the past 3 months. She had normal cervical screening 18 months ago. On speculum examination, the cervix appears normal. Transvaginal ultrasound shows endometrial thickness of 18 mm with heterogeneous appearance. What is the most appropriate next investigation?
A. Repeat transvaginal ultrasound in 3 months
B. Hysteroscopy with endometrial biopsy (Correct Answer)
C. Saline infusion sonography
D. Serum CA-125 measurement
E. MRI pelvis
Explanation: ***Hysteroscopy with endometrial biopsy***
- In a 52-year-old perimenopausal woman with **intermenstrual bleeding** and **post-coital bleeding**, combined with an **18 mm heterogeneous endometrial thickness** on ultrasound, there is a high suspicion for **endometrial hyperplasia** or **malignancy**.
- **Hysteroscopy** allows for direct visualization of the endometrial cavity and targeted **endometrial biopsy**, which is the gold standard for obtaining a **histological diagnosis**.
*Repeat transvaginal ultrasound in 3 months*
- This option is inappropriate as it would cause a significant and potentially dangerous delay in diagnosing a possible **endometrial cancer** or **pre-malignant condition**.
- Given the patient's age, symptoms, and the highly abnormal **endometrial thickness**, immediate **histological evaluation** is required.
*Saline infusion sonography*
- While **saline infusion sonography (SIS)** can help delineate intrauterine lesions like **polyps** or **submucosal fibroids**, it is an imaging technique and does not provide a **tissue diagnosis**.
- It cannot replace the need for an **endometrial biopsy** in a patient with a thickened, heterogeneous endometrium and abnormal bleeding, where malignancy is a concern.
*Serum CA-125 measurement*
- **CA-125** is primarily a tumor marker for **ovarian cancer** and is not routinely used as an initial diagnostic test for **abnormal uterine bleeding** or **endometrial pathology**.
- A normal **CA-125** level would not rule out **endometrial cancer** and would not negate the need for **endometrial sampling**.
*MRI pelvis*
- **MRI pelvis** is typically reserved for **staging confirmed gynecological cancers** or for evaluating complex pelvic masses, not as an initial diagnostic investigation for abnormal uterine bleeding with a thickened endometrium.
- It is more expensive and, critically, does not provide the **histological diagnosis** necessary to differentiate between benign and malignant endometrial conditions.
Question 138: A 32-year-old nulliparous woman presents with 6 weeks amenorrhoea and mild lower abdominal pain. Transvaginal ultrasound shows an empty uterus with 15 mm endometrial thickness and a 25 mm adnexal mass with a hyperechoic ring. Serum beta-hCG is 2,100 IU/L. She is haemodynamically stable and wishes to preserve her fertility. A repeat beta-hCG 48 hours later is 3,800 IU/L. What is the most appropriate management?
A. Expectant management with serial beta-hCG monitoring
B. Methotrexate therapy (Correct Answer)
C. Laparoscopic salpingectomy
D. Laparoscopic salpingotomy
E. Uterine curettage
Explanation: ***Methotrexate therapy***- The patient has an **unruptured ectopic pregnancy** and is **hemodynamically stable**, making her a candidate for medical management to preserve fertility.- With a **serum beta-hCG <5,000 IU/L** (specifically 3,800 IU/L) and an adnexal mass **<35 mm** without a fetal heartbeat, **Methotrexate** is the preferred pharmacological intervention.*Expectant management with serial beta-hCG monitoring*- This approach is generally reserved for patients with very low and **decreasing beta-hCG levels** (typically <1,500 IU/L).- In this case, the **rising beta-hCG** (from 2,100 to 3,800 IU/L) indicates a proliferating pregnancy that requires active treatment.*Laparoscopic salpingectomy*- This involves the **surgical removal of the fallopian tube**, which is typically indicated for patients with a ruptured ectopic or significant pain.- While effective, it is less desirable for a stable patient specifically wishing to **preserve her fertility** and tubal integrity.*Laparoscopic salpingotomy*- This surgical procedure involves opening the tube to remove the pregnancy; however, it carries a risk of **persistent trophoblastic tissue**.- It is usually reserved for patients with a **contralateral tubal abnormality** when medical management is contraindicated or unsuccessful.*Uterine curettage*- This procedure is used to rule out an **incomplete miscarriage** but has no role in the management of a confirmed extrauterine adnexal mass.- Performing a curettage in this clinical scenario would be inappropriate as the **ultrasound and rising hCG** confirm an ectopic pregnancy rather than a failed intrauterine one.
Question 139: A 45-year-old woman attends the gynaecology clinic with a 6-month history of increasingly heavy menstrual bleeding. Her periods occur regularly every 28 days but last 9 days with flooding and clots. She has completed her family. Blood tests show haemoglobin 95 g/L, MCV 72 fL. Transvaginal ultrasound reveals a normal-sized uterus with 12 mm endometrial thickness and no structural abnormalities. What is the most appropriate first-line pharmacological treatment?
A. Combined oral contraceptive pill
B. Tranexamic acid
C. Levonorgestrel intrauterine system (Correct Answer)
D. Gonadotrophin-releasing hormone analogues
E. Norethisterone
Explanation: ***Levonorgestrel intrauterine system***
- The **LNG-IUS (Mirena/Levosert)** is recommended by **NICE guidelines** as the first-line pharmacological treatment for **heavy menstrual bleeding (HMB)** in women with no structural/histological abnormalities.
- It provides highly effective **long-term contraception** and significantly reduces blood loss by causing **endometrial atrophy**, making it suitable for this patient who has completed her family.
*Combined oral contraceptive pill*
- While it can regulate periods and reduce flow, it is considered a **second-line** option compared to the LNG-IUS for HMB.
- The risks associated with the **combined oral contraceptive pill**, such as VTE, may be higher in women over 35, requiring careful assessment of **UKMEC criteria**.
*Tranexamic acid*
- This is an **antifibrinolytic** taken only during the period; it is a first-line alternative for women who do not want or cannot use **hormonal treatments**.
- Although effective at reducing blood loss, it does not provide **contraception** or the superior long-term flow reduction seen with the LNG-IUS.
*Gonadotrophin-releasing hormone analogues*
- These agents induce a **hypoestrogenic state** and are typically reserved for **pre-operative** shrinking of fibroids or as a second-line specialist treatment.
- Their use is limited to **short-term** (usually <6 months) due to the risk of **osteoporosis** and menopausal symptoms.
*Norethisterone*
- Cyclic oral **progestogens** like Norethisterone are less effective than other treatments for HMB and are no longer recommended as a primary first-line choice.
- It is generally used for **short-term control** of acute bleeding rather than the long-term management of chronic HMB.
Question 140: A 28-year-old woman presents to the emergency department with sudden onset severe left iliac fossa pain and vaginal bleeding. Her last menstrual period was 7 weeks ago. She has a history of pelvic inflammatory disease. On examination, she is pale, blood pressure 95/60 mmHg, pulse 110 bpm. Abdominal examination reveals tenderness and guarding in the left iliac fossa. A urine pregnancy test is positive. What is the most appropriate immediate management?
A. Arrange urgent transvaginal ultrasound scan
B. Administer intramuscular methotrexate
C. Initiate resuscitation and arrange emergency laparotomy (Correct Answer)
D. Measure serum beta-hCG levels
E. Perform diagnostic laparoscopy
Explanation: ***Initiate resuscitation and arrange emergency laparotomy***
- The patient exhibits features of a **ruptured ectopic pregnancy** with **hemodynamic instability** (hypotension, tachycardia, and pallor), necessitating immediate life-saving intervention.
- **Resuscitation** with intravenous fluids and blood products alongside an **emergency laparotomy** is mandatory to control hemorrhage when a patient is in **hypovolemic shock**.
*Arrange urgent transvaginal ultrasound scan*
- While ultrasound is useful for diagnosing stable ectopic pregnancies, it should not delay treatment in an **unstable patient** with clinical evidence of rupture.
- Clinical diagnosis of a **surgical emergency** takes precedence over imaging in the presence of **peritonitis** and shock.
*Administer intramuscular methotrexate*
- **Methotrexate** is a medical management option reserved exclusively for **stable, unruptured** ectopic pregnancies with low beta-hCG levels.
- It is strictly contraindicated in cases of **hemodynamic instability** or suspected rupture due to the high risk of fatal hemorrhage.
*Measure serum beta-hCG levels*
- **Serum beta-hCG** is used to monitor pregnancy viability or location in stable patients but adds no value in an acute **rupture** scenario.
- Waiting for laboratory results would cause a dangerous delay in the **surgical management** required to save the patient's life.
*Perform diagnostic laparoscopy*
- **Laparoscopy** is the gold standard for stable patients; however, in a state of **hypovolemic shock**, the increased intra-abdominal pressure from insufflation can worsen hemodynamic collapse.
- **Laparotomy** is generally preferred in the unstable patient to allow for faster access and better control of **massive hemoperitoneum**.
